Shanghai Haohai Biological Technology (6826) Fundamentals 2026 — P/E 31.5x, Revenue Analysis | SniperIQ
Shanghai Haohai Biological Technology (6826) is a CN-listed Healthcare company in Biotechnology with a market capitalization of HK$6.6B, trading at HK
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Shanghai Haohai Biological Technology's market cap?
Shanghai Haohai Biological Technology (6826) has a market capitalization of approximately HK$6.6B, trading at HK
What is Shanghai Haohai Biological Technology's P/E ratio?
Shanghai Haohai Biological Technology's trailing twelve-month P/E ratio is 31.5x, with a price-to-book (P/B) of 1.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Shanghai Haohai Biological Technology?
Shanghai Haohai Biological Technology runs a net profit margin of 9.7%, a gross margin of 99.8%, and an operating margin of 7.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Shanghai Haohai Biological Technology generate?
Shanghai Haohai Biological Technology reported revenue of ¥2.4B for fiscal year 2025, with net income of ¥245M and earnings per share (EPS) of 1.08. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Shanghai Haohai Biological Technology pay a dividend?
Shanghai Haohai Biological Technology offers a trailing dividend yield of about 3.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Shanghai Haohai Biological Technology financially healthy?
Shanghai Haohai Biological Technology carries a debt-to-equity ratio of 0.08x and a current ratio of 3.73x, with a market beta of 0.45. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Shanghai Haohai Biological Technology a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Shanghai Haohai Biological Technology (6826) the key facts are: market cap HK$6.6B, P/E 31.5x, revenue ¥2.4B, 52-week range 15.04-31.28. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Shanghai Haohai Biological Technology's full fundamentals live
Get Shanghai Haohai Biological Technology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.